Valuation: Merus N.V.

Capitalization 4.06B 3.47B 3.23B 3.01B 5.56B 348B 6.17B 38.74B 14.81B 163B 15.22B 14.91B 598B P/E ratio 2025 *
-11.5x
P/E ratio 2026 * -12.3x
Enterprise value 3.57B 3.05B 2.84B 2.64B 4.88B 306B 5.43B 34.05B 13.02B 143B 13.38B 13.11B 526B EV / Sales 2025 *
64x
EV / Sales 2026 * 69x
Free-Float
97.53%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-1.11%
1 week+1.26%
Current month+3.61%
1 month-1.00%
3 months+29.85%
6 months+24.29%
Current year+29.61%
More quotes
1 week 51.78
Extreme 51.78
55.3
1 month 51.78
Extreme 51.78
56.2
Current year 33.19
Extreme 33.19
62.98
1 year 33.19
Extreme 33.19
62.98
3 years 12.03
Extreme 12.03
62.98
5 years 10.18
Extreme 10.18
62.98
10 years 7.26
Extreme 7.255
62.98
More quotes
Manager TitleAgeSince
Chief Executive Officer 61 30/12/2019
Director of Finance/CFO 64 13/06/2023
Chief Tech/Sci/R&D Officer - 30/11/2016
Director TitleAgeSince
Chairman 58 30/04/2015
Chairman 49 31/05/2020
Director/Board Member 63 30/06/2018
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-1.11%+1.26%-2.40%+135.02% 4.06B
-1.01%+2.87%+11.77%+33.47% 34.39B
+9.99%+8.94%+98.74%-28.56% 30.84B
-0.90%+2.63%+33.28%-32.19% 27.8B
+1.57%+0.39%+27.46%+321.37% 18.65B
-3.40%+1.83%+188.02%+2,400.00% 18.57B
+3.70%+1.72%+139.66%-65.41% 13.81B
-1.18%+6.12%-23.36%-44.81% 13.28B
+4.52%-2.50%+195.56%+385.84% 12.94B
-0.69%-2.80%+98.94%+117.45% 12.23B
Average +1.15%+3.09%+76.77%+322.22% 18.66B
Weighted average by Cap. +1.58%+4.20%+73.58%+296.97%
See all sector performances

Financials

2025 *2026 *
Net sales 55.73M 47.65M 44.39M 41.28M 76.28M 4.78B 84.77M 532M 203M 2.24B 209M 205M 8.21B 55.34M 47.32M 44.08M 41M 75.75M 4.75B 84.19M 528M 202M 2.22B 208M 203M 8.16B
Net income -334M -285M -266M -247M -457M -28.63B -508M -3.18B -1.22B -13.4B -1.25B -1.23B -49.17B -331M -283M -264M -246M -454M -28.43B -504M -3.16B -1.21B -13.31B -1.24B -1.22B -48.83B
Net Debt -491M -420M -391M -364M -672M -42.12B -747M -4.69B -1.79B -19.72B -1.84B -1.8B -72.35B -238M -203M -190M -176M -326M -20.41B -362M -2.27B -868M -9.56B -892M -874M -35.06B
More financial data * Estimated data
Logo Merus N.V.
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.
Employees
291
More about the company
Date Price Change Volume
11/07/25 54.50 $ -1.11% 315,953
10/07/25 55.11 $ +1.10% 695,442
09/07/25 54.51 $ +4.17% 1,303,848
08/07/25 52.33 $ -0.48% 450,998
07/07/25 52.58 $ -2.30% 354,790

Delayed Quote Nasdaq, July 11, 2025 at 09:00 pm

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
54.50USD
Average target price
90.20USD
Spread / Average Target
+65.50%
Consensus

Quarterly revenue - Rate of surprise